

sanofi

EU SPC System and uSPC: What to be expected?

Brigitte Carion-Taravella


ASPI-AIPPI-LES / Life Science Conference 07.06.2022

- 01 The EU legal context IN THE PHARMACEUTCICALS FIELD
- 02 SPC current practices
- 03 Areas for improvements
- 04 Practioner's positions

The EU legal context

Pharmaceutical Regulatory Outlook





- 01 The EU legal context IN THE PHARMACEUTCICALS FIELD
- 02 SPC current practices
- 03 Areas for improvements
- 04 Practioner's positions

SPC Current Practices

Based on a National or European Patent

Based on a National or Community Market Approval Granted by the national patent office of each EU Member State

European Regulations No. 469/2009 for medicinal products

Litigate with the competence of the national authorities



- 01 The EU legal context IN THE PHARMACEUTCICALS FIELD
- 02 SPC current practices
- 03 Areas for improvements
- 04 Practioner's positions

Areas for improvements

More transparency of information More harmonization More centralization and Less administrative burden Less costly and less complex Greater harmonization of SPC decisions More legal certainty

- 01 The EU legal context IN THE PHARMACEUTCICALS FIELD
- 02 SPC current practices
- 03 Areas for improvement
- 04 **Practioner's positions**

Practioners are in majority in Favor of ...



No double SPC protection



Practioners are in disagreements about ...

Opposition mechanism

Re-opening of the SPC regulation

Appeal instance

Next Steps

As identifed by the European Commsiion



Status quo → No change

Guidelines or « Good Practices »

Legislative changes



